<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020134</url>
  </required_header>
  <id_info>
    <org_study_id>ASC162002</org_study_id>
    <nct_id>NCT03020134</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China</brief_title>
  <official_title>Phase I Study of Pharmacokinetics and Safety of Ravidasvir in Combination With Ritonavir-boosted Danoprevir in Single and Multiple Doses in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetics and safety of Ravidasvir in
      Combination with Ritonavir-boosted Danoprevir in Single and Multiple doses in Healthy
      Participants
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>40 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration at steady-state (Css,max)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Total area under the concentration-time curve form time 0 to 12 hours post-dose at steady-state</measure>
    <time_frame>Up to 24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PKGroup(Ravidasvir/Danoprevir/Ritonavir)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ravidasvir + Danoprevir/ Ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir</intervention_name>
    <description>Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23</description>
    <arm_group_label>PKGroup(Ravidasvir/Danoprevir/Ritonavir)</arm_group_label>
    <other_name>ASC16(RDV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23</description>
    <arm_group_label>PKGroup(Ravidasvir/Danoprevir/Ritonavir)</arm_group_label>
    <other_name>ASC08 (DNV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23</description>
    <arm_group_label>PKGroup(Ravidasvir/Danoprevir/Ritonavir)</arm_group_label>
    <other_name>RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Overall health situation is good according to disease history, physical exam, physical
             symptoms, laboratory tests and 12 lead ECG.

          -  If female, surgically sterilized or willingness to use reliable method of birth
             control during the study and for 30 days after the last dose of study medication.

          -  If male, surgically sterilized or willingness to use reliable method of birth control
             during the study and for 30 days after the last dose of study medication.

          -  If female, negative pregnancy test during the screening period.

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  History or presence of cardiovascular disease, respiratory disease, endocrine and
             metabolic system disease, urinary system, digestive system, hematological system
             diseases, nervous system or Psychiatric diseases, and acute or chronic infectious
             disease and malignant tumor.

          -  Positive test in any of the HAV-IgM,HBsAg, HCV Ab, HIV Ab, Syphilis Ab

          -  History of gastrointestinal surgery, trunk vagotomy, intestinal excision or any other
             surgeries that could disturb gastrointestinal motility and PH absorption.

          -  Female during pregnancy, breastfeeding, period and unwilling to take reliable birth
             control method.

          -  Others as specified in the detailed protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huoling Tang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Danoprevir/r</keyword>
  <keyword>Ravidasvir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

